Extrapyramidal reactions and the selective serotonin-reuptake inhibitors

Annals of Pharmacotherapy

Volumn 31, Issue 12, 1997, Pages 1481-1489

  Caley, Charles F ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b INSTITUTE OF LIVING   (United States)

Author keywords

Extrapyramidal reactions; Psychotropics; Selective serotonin reuptake inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; CARBAMAZEPINE; CIMETIDINE; CLONAZEPAM; CLONIDINE; CYCLOPHOSPHAMIDE; DICLOFENAC; DOXEPIN; FAMOTIDINE; FLUOXETINE; FLUPHENAZINE; GLIPIZIDE; IBUPROFEN; LEVOTHYROXINE; LITHIUM; MECLOZINE; METOCLOPRAMIDE; PAROXETINE; PILOCARPINE; RANITIDINE; SALBUTAMOL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TEMAZEPAM; TERAZOSIN; TIOTIXENE; TRAZODONE; TRIAZOLAM; TRYPTOPHAN; UNINDEXED DRUG;

AKATHISIA; DEPRESSION; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPOTHESIS; MEDICAL INFORMATION; MEDICAL LITERATURE; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; REVIEW;

EID: 0031436241     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703101208     Document Type: Review

References (47)

1. Addonizio G, Roth SD, Stokes PE, Stoll PM. Increased extrapyramidal symptoms with addition of lithium to neuroleptics. J Nerv Ment Dis 1988;176:682-5.
2. Krishnan KRR, France RD, Ellinwood EH. Tricyclic-induced akathisia in patients taking estrogens. Am J Psychiatry 1984;141:696-7.
3. Zubenko GS, Cohen BM, Lipinski JF. Antidepressant-related akathisia. J Clin Psychopharmacol 1987;7:254-7.
4. Lee HK. Dystonic reactions to amitriptyline and doxepin (letter). Am J Psychiatry 1988;145:649.
5. Fishbain DA, Dominguez M, Goldberg M, Olsen E, Rosomoff H. Dyskinesia associated with fluoxetine use: case report. Neuropsychiatry Neuropsychol Behav Neurol 1992;5:97-100.
6. Suranyi-Cadotte BE, Nestoros JN, Nair NPV, Gauthier S. Parkinsonism induced by high doses of diazepam. Biol Psychiatry 1985;20:451-60.
7. Jacobs MB. Diltiazem and akathisia. Ann Intern Med 1983;99:794-5.
8. Bernick C. Methysergide-induced akathisia. Clin Neuropharmacol 1988; 11:87-9.
9. Chase TN, Ng LKY, Watanabe AM. Parkinson's disease: modification by 5-hydroxytryptophan. Neurology 1972;22:479-84.
10. Brandon S. Unusual effect of fenfluramine (letter). Br Med J 1969;5: 557-8.
11. Sananman ML. Dyskinesia after fenfluramine (letter). N Engl J Med 1974;291:422.
12. Guyton AC. Motor functions of the brain stem and basal ganglia -reticular formation, vestibular apparatus, equilibrium, and brain stem reflexes. In: Dreibelbis D, ed. Textbook of medical physiology. Philadelphia: WB Saunders Co., 1986:619-31.
13. Hamilton MS, Opler LA. Akathisia, suicidality, and fluoxetine. J Clin Psychiatry 1992;53:401-6.
14. Dopamine. In: Cooper JR, Bloom FE, Roth RH, eds. The biochemical basis of neuropharmacology. 6th ed. New York: Oxford University Press, 1991:285-337.
15. Serotonin (5-hydroxytryptamine) and histamine. In: Cooper JR, Bloom FE, Roth RH, eds. The biochemical basis of neuropharmacology. 6th ed. New York: Oxford University Press, 1991:338-80.
16. Lipinski JF, Mallya G, Zimmerman P, Pope HG. Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry 1989; 50:339-42.
17. Meltzer HY, Young M, Metz J, Fang VS, Schyve PM, Arora RC. Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm 1979;45:165-75.
18. Reccoppa L, Welch WA, Ware MR. Acute dystonia and fluoxetine (letter). J Clin Psychiatry 1990;51:487.
19. Ketai R. Interaction between fluoxetine and neuroleptics (letter). Am J Psychiatry 1993;150:836-7.
20. George MS, Trimble MR. Dystonic reaction associated with fluvoxamine (letter). J Clin Psychopharmacol 1993;13:220-1.
21. Rothschild AJ, Locke CA. Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. J Clin Psychiatry 1991; 52:491-3.
22. Lavin MR, Mendelowitz A, Block SH. Adverse reaction to high-dose fluoxetine (letter). J Clin Psychopharmacol 1993;13:452-3.
23. Fallon BA, Liebowitz MR. Fluoxetine and extrapyramidal symptoms in CNS lupus (letter). J Clin Psychopharmacol 1991;11:147-8.
24. LaPorta LD. Sertraline-induced akathisia (letter). J Clin Psychopharmacol 1993;13:219-20.
25. Adler LA, Angrist BM. Paroxetine and akathisia. Biol Psychiatry 1995;37:336-7.
26. Baldassano CF, Truman CJ, Nierenberg A, Ghaemi SN, Sachs GS. Akathisia: a review and case report following paroxetine treatment. Compr Psychiatry 1996;37:122-4.
27. Halman M, Goldbloom DS. Fluoxetine and neuroleptic malignant syndrome. Biol Psychiatry 1990;28:518-21.
28. Budman CL, Bruun RD. Persistent dyskinesia in a patient receiving fluoxetine (letter). Am J Psychiatry 1991;148:1403.
29. Sandler NH. Tardive dyskinesia associated with fluoxetine (letter). J Clin Psychiatry 1996;57:91.
30. Dubovsky SL, Thomas M. Tardive dyskinesia associated with fluoxetine. Psychiatr Serv 1996;47:991-3.
31. Mander A, McCausland M, Workman B, Flamer H, Christophidis N. Fluoxetine induced dyskinesia. Aust N Z J Psychiatry 1994;28:328-30.
32. Botsaris SD, Sypek JM. Paroxetine and tardive dyskinesia (letter). J Clin Psychopharmacol 1996;16:258-9.
33. Täte JL. Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine (letter). Am J Psychiatry 1989;146:399-400.
34. Bouchard RH, Pourcher E, Vincent P. Fluoxetine and extrapyramidal side effects (letter). Am J Psychiatry 1989;146:1352-3.
35. Brod TM. Fluoxetine and extrapyramidal side effects (letter). Am J Psychiatry 1989;146:1353.
36. Austin LS, Arana GW, Melvin JA. Toxicity resulting from lithium augmentation of antidepressant treatment in elderly patients. J Clin Psychiatry 1990;51:344-5.
37. Malek-Ahmadi P, Allen SA. Paroxetine-molindone interaction (letter). J Clin Psychiatry 1995;56:82-3.
38. Wils V. Extrapyramidal symptoms in a patient treated with fluvoxamine (letter). J Neurol Neurosurg Psychiatry 1992;55:330-1.
39. Chouinard G, Sultan S. A case of Parkinson's disease exacerbated by fluoxetine (letter). Hum Psychopharmacol 1992;7:63-6.
40. Jansen Steur ENH. Increase of Parkinsonism disability after fluoxetine medication. Neurology 1993;43:211-3.
41. Jiménez-Jiménez FJ, Tejeiro J, Martínez-Junquera G, Cabrera-Valdivia F, Alarcón J, García-Albea E. Parkinsonism exacerbated by paroxetine (letter). Neurology 1994;44:2406.
42. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-13.
43. Seibyl JP, Glazer WM, Innis RB. Serotonin function in tardive dyskinesia. Psychiatr Ann 1989;19:310-4.
44. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson's disease. Vol. 2. Florham Park, NJ: Macmillan Healthcare Informations, 1987:153-64.
45. DeVane CL. Pharmacokinetics of the newer antidepressants: clinical relevance. Am J Med 1994;97(suppl 6A):13S-23S.
46. DeVane CL. Pharmacogenetics and drug metabolism of newer antidepressants. J Clin Psychiatry 1994;55(suppl 12):38-45.
47. Caley CF, Friedman JH. Does fluoxetine exacerbate Parkinson's disease? J Clin Psychiatry 1992;53:278-82.